Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A 29-year-old man shows 3 months of hair regrowth using minoxidil 5%, oral dutasteride 0.5mg every other day, and occasional microneedling after overcoming fears about finasteride side effects. He is optimistic about further improvement.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A 29-year-old male is experiencing positive hair regrowth after 3 months using oral finasteride (1mg) and topical minoxidil (1ml twice daily), despite side effects like scalp itchiness and dandruff. He plans to continue the treatment long-term and may switch to foam minoxidil to alleviate scalp issues.

A user reported hair regrowth using a homemade topical solution of minoxidil and finasteride sourced from Pakistan, combined with microneedling, after experiencing hair loss with UK-based products. They claim a reduction in hair loss from 200-300 to 3-5 hairs a day and advise against spending money on branded products.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.